<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An increased risk of <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> has been reported in systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (<z:hpo ids='HP_0100324'>scleroderma</z:hpo>) </plain></SENT>
<SENT sid="1" pm="."><plain>Periodic endoscopic or radiologic surveillance, or both, of systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux</z:hpo> symptoms has been recommended for early detection of Barrett's mucosa and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>A review of 680 closely followed systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> patients for <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> of <z:hpo ids='HP_0000001'>all</z:hpo> types, and of a 22-yr experience with esophageal and esophagogastric junction <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and undifferentiated <z:mp ids='MP_0002038'>carcinoma</z:mp>, did not reveal a significant increase in the frequency of <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> in systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Regular surveillance for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> would not appear to be cost-effective because of the rarity of <z:mp ids='MP_0002038'>carcinoma</z:mp>, increased patient discomfort and expense, and the questionable benefit for long-term survival </plain></SENT>
</text></document>